Clinical trial
To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine…
NCT00346892 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00346892 |
|---|---|
| Title | To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV |
| Official title | Reactogenicity & Immunogenicity Study of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Co-administered With Either OPV or IPV in Healthy Infants (Approximately 5-10 Weeks Old) in South Africa |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rotavirus Infections |
| Intervention type | Biological |
| Interventions | Rotavirus (vaccine) |
| Enrollment | 450 |
| Start date | Nov 1, 2001 |
| Primary completion | Mar 1, 2003 |
| First posted | Jun 30, 2006 |
| Last update posted | Sep 9, 2016 |
| Countries | South Africa |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: